ABSTRACT
OBJECTIVES: To evaluate the role of transvaginal ultrasound (TVUS) for diagnosing cervical invasion in the preoperative assessment of endometrial carcinoma. METHODS: A search for studies evaluating the role of TVUS for assessing cervical invasion in endometrial carcinoma from January 1990 to December 2016 was performed in the PubMed/MEDLINE, Web of Science, www.ClinicalTrials.gov, and www.who.int/trialsearchdatabases. The quality of the studies was evaluated by the Quality Assessment of Diagnostic Accuracy Studies 2. RESULTS: We identified 211 citations. Ultimately, 17 studies comprising 1751 women were included. The mean prevalence of cervical invasion was 16.3%. The risk of bias was high in 7 studies for the domains "patient selection" and "index test," whereas it was considered low for the "reference test" domain. Overall, the pooled estimated sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of TVUS for detecting cervical invasion were 63% (95% confidence interval [CI], 51%-74%), 91% (95% CI, 87%-94%), 10.2 (95% CI, 5.7-18.3), and 0.38 (95% CI, 0.28-0.53), respectively. Heterogeneity was high for both sensitivity and specificity. CONCLUSIONS: Transvaginal ultrasound has acceptable diagnostic performance for detecting cervical invasion in women with endometrial carcinoma.
Subject(s)
Endometrial Neoplasms/pathology , Uterine Cervical Neoplasms/diagnostic imaging , Uterine Cervical Neoplasms/secondary , Cervix Uteri/diagnostic imaging , Female , Humans , Neoplasm Invasiveness , Reproducibility of Results , Sensitivity and Specificity , Ultrasonography/methods , Vagina/diagnostic imagingABSTRACT
Fundamento y objetivo. La degeneración cerebelosa paraneoplásica (DCP) es una complicación neurológica infrecuente que aparece en pacientes con cáncer y se asocia a diferentes autoanticuerpos. La DCP asociada a anticuerpos anti-Yo ocurre más frecuentemente en pacientes con cáncer ginecológico. El uso de un método diagnóstico que permita su detección precoz y una adecuada conducta terapéutica no están establecidos. Métodos. Se describen 3 casos clínicos correspondientes a pacientes que comenzaron con disfunción cerebelar subaguda y anticuerpos anti-Yo positivos. Tras el diagnóstico y tratamiento del proceso oncológico y el cuadro neurológico, se realizó un seguimiento clínico para evaluar la evolución del síndrome neurológico. Resultados. Se realizaron estudios de imagen complementarios para descartar un cáncer ginecológico. La tomografía por emisión de positrones/tomografía computarizada con fluorodesoxiglucosa (FDG-PET/TC) fue la única exploración de imagen que sospechó la lesión primaria en todos los casos. El estudio histológico confirmó carcinoma de ovario en 2 casos y carcinoma de trompa en un caso. Las pacientes fueron tratadas mediante cirugía radical y quimioterapia adyuvante. Se administraron corticoides sin observar ninguna mejoría del síndrome neurológico. Conclusión. El tratamiento oncológico no modificó los síntomas neurológicos. La FDG-PET/TC puede ser útil en algunos casos de DCP en los que las exploraciones de imagen convencionales no identifican la neoplasia subyacente (AU)
Background and objective. Paraneoplastic cerebellar degeneration (PCD) is a rare neurological complication that develops in patients with cancer and is associated with different antibodies. PCD associated with anti-Yo antibodies usually occurs in patients with gynecological cancer. There is no diagnostic method that would allow early detection and appropriate treatment. Methods. We describe three patients who presented with subacute cerebellar dysfunction and positive anti-Yo antibodies. After diagnosis and treatment, the patients were monitored to evaluate persistence of the neurological syndrome. Results. Imaging studies were performed when gynecologic cancer was suspected. In all patients, fluorodeoxyglucose-positron emission tomography/tomography computerized (FDG-PET/TC) was the only imaging test that led to suspicion of the primary lesion. Histological examination confirmed the diagnosis of ovarian carcinoma in two patients and carcinoma of the horn in the third patient. All patients underwent radical surgery and subsequent chemotherapy. Corticosteroids were administered with no improvement of the neurological syndrome in any of the patients. Conclusion. Oncologic treatment does not improve neurological symptoms. FDG-PET/TC with fluorodeoxyglucose could be useful in cases of PCD in which conventional imaging tests do not identify the underlying malignancy (AU)
